Is Applied Materials (AMAT) Quietly Rewiring Its AI Moat With New DRAM And Packaging Tools? – Yahoo Finance UK

Home AI Is Applied Materials (AMAT) Quietly Rewiring Its AI Moat With New DRAM And Packaging Tools? – Yahoo Finance UK
Is Applied Materials (AMAT) Quietly Rewiring Its AI Moat With New DRAM And Packaging Tools? – Yahoo Finance UK

Something went wrong
In recent days, Applied Materials introduced a new epitaxy system for DRAM, plus CMP, deposition and eBeam tools aimed at advanced 3D packaging and high-bandwidth memory to support next-generation AI chips.
This push ties front-end transistor engineering and back-end packaging control more tightly together, potentially deepening Applied’s role across the full AI semiconductor manufacturing flow.
We’ll now examine how Applied’s expanded DRAM epitaxy and advanced packaging toolkit could influence its AI-focused investment narrative.
Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
To own Applied Materials today, you need to believe that AI driven demand for leading edge logic, DRAM and advanced packaging will keep pulling more wafer fab equipment spending toward the company’s core strengths, even as export controls, China exposure and rich valuation remain key swing factors. The new DRAM epitaxy and advanced packaging tools reinforce the bull case around HBM and AI, but do not materially change the near term risk that demand or spending timing could wobble.
The announcement most connected to this DRAM and HBM push is Applied’s earlier launch of the Centris Spectral SiN ALD and Producer Selectra Mo Etch systems, which also target difficult 3D structures in leading edge memory and logic. Together with the new epitaxy, CMP, deposition and eBeam platforms, these tools sketch a consistent story: Applied is trying to be designed into more of the AI chip stack, from transistor channels to stacked HBM packages, across multiple customer roadmaps.
Yet while the growth story is powerful, investors should also weigh how much of it is already priced in and what happens if China related headwinds or a slowdown in DRAM equipment spending…
Read the full narrative on Applied Materials (it’s free!)
Applied Materials’ narrative projects $49.4 billion revenue and $16.5 billion earnings by 2029. This requires 19.4% yearly revenue growth and an $8.0 billion earnings increase from $8.5 billion today.
Uncover how Applied Materials’ forecasts yield a $511.17 fair value, a 23% downside to its current price.
Some of the lowest ranked analysts were already assuming only about 15% annual revenue growth and US$12.4 billion of earnings by 2029, and they worry that export controls and weaker DRAM orders from China could blunt the impact of new AI tools more than the bullish camp expects, so if you are weighing this new product news it is worth knowing just how far apart these views can be.
Explore 11 other fair value estimates on Applied Materials – why the stock might be worth as much as $575.00!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
A great starting point for your Applied Materials research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
Our free Applied Materials research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Applied Materials’ overall financial health at a glance.
The market won’t wait. These fast-moving stocks are hot now. Grab the list before they run:
Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AMAT.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Sign in to access your portfolio

source

Leave a Reply

Your email address will not be published.